Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hycroft Mining Holding Corporation Class A Common Stock (HYMC) vs Ionis Pharmaceuticals Inc. Common Stock (IONS) Price & Performance

Hycroft Mining Holding Corporation Class A Common StockTrade
Ionis Pharmaceuticals Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Hycroft Mining Holding Corporation Class A Common Stock vs Ionis Pharmaceuticals Inc. Common Stock — how do they compare? Hycroft Mining Holding Corporation Class A Common Stock trades at $16.72 (market cap $1.64B), while Ionis Pharmaceuticals Inc. Common Stock trades at $43.2 (market cap $7.04B). The key difference: Ionis Pharmaceuticals Inc. Common Stock is far larger — about 4.3× Hycroft Mining Holding Corporation Class A Common Stock's market cap, and Hycroft Mining Holding Corporation Class A Common Stock is trading nearer its 52-week high, Ionis Pharmaceuticals Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hycroft Mining Holding Corporation Class A Common Stock for 0 Days and Ionis Pharmaceuticals Inc. Common Stock for 0 Days on average.

HYMCIONS
Market Cap
$1.64B$7.04B
Volume
1,750,0982,977,440
Sector
Basic MaterialsHealth
52-Week High
$55.74$86.50
52-Week Low
$6.75$42.38
Typical Hold Time
0 Days0 Days
Enterprise Value
$1.42B$6.60B

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HYMC
100% Buy0% Sell
Avg holding period · 0 Days
IONS
100% Buy0% Sell
Avg holding period · 0 Days

About Hycroft Mining Holding Corporation Class A Common Stock

Hycroft Mining Holding Corporation is a US mining company that owns and operates the Hycroft Mine, a gold and silver deposit in northern Nevada, producing and selling gold and silver from open-pit mining operations.

Read more on HYMC →

About Ionis Pharmaceuticals Inc. Common Stock

Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.

Read more on IONS →